The 2017 update now divides AML into three (instead of four) risk groups (i.e., favorable, intermediate and adverse), based on the results of conventional cytogenetics and single gene mutations in NPM 1, FLT3, biallelic CEBPA, RUNX, ASXL1 and TP53 [24]. The gene discussed is ASXL1; the disease is acute myeloid leukemia.